Copyright © 2021. Inderes Oyj. All rights reserved.

The Annual General Meeting adopted the following resolutions:

  • The Balance Sheet and Income Statement as well as the Consolidated Income Statement and the Consolidated Balance Sheet were adopted.

  • The Board and the Chief Executive Officer were discharged from liability.

  • The Board shall consist until the next AGM of five ordinary members without deputies.

  • Re-election of Board membersTorben Jørgensen,Mikael Lönn, Kenth Petersson and Lotta Ljungqvist.

Steve Jordanwas elected new Board member.

Torben Jørgensenwas elected Chairperson of the Board.
  • Remuneration will be paid to the Board of Directors in the amount of SEK 150,000 to Board members and SEK 300,000 to the Chairperson of the Board. 

  • The Meeting approved the Board of Directors' report regarding compensation pursuant to Chapter 8, Section 53 a of the Swedish Companies Act.

  • Remuneration to the auditors will be paid on approved account.  

  • In accordance with the Nomination Committee's proposal, the Meeting re-elected the accounting firm Öhrlings PricewaterhouseCoopers AB as auditor for the period until the close of the Annual General Meeting 2022.

  • A Nomination Committee will be formed with representatives of the four largest shareholders at September 30, 2021.

  • The AGM resolved on the authorization to issue shares with or without preferential rights for existing shareholders. As a result of this resolution, share capital could increase by a maximum of SEK 1,625,000 through the issuance of a maximum of 6,500,000 shares.


Genovis AB provides enzymes and technologies for analytical characterization and conjugation of biopharmaceuticals. The principal activities of the company are to develop, produce and market tools for developing new drugs and diagnostics. The Genovis product line comprises of GingisREX, FabRICATOR, GlyCLICK, GingisKHAN, GlycINATOR, Fabulous, lgGZERO, and Enzymes for O-glycan. The company serves mainly the medical device and pharmaceutical industries.